Human antithrombin III concentrate - Octapharma
Latest Information Update: 04 Apr 2023
At a glance
- Originator Octapharma
- Class Anticoagulants; Antithrombins; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Antithrombin III deficiency
Most Recent Events
- 01 Jul 2022 Phase-III clinical trials in Antithrombin III deficiency (In adults, In children, In the elderly) in USA, Hungary, Spain, France (Infusion) (NCT04918173)